Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EPS (Basic): 2021-2025

Historic EPS (Basic) for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -$0.44.

  • InMed Pharmaceuticals' EPS (Basic) rose 83.76% to -$0.44 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.45, marking a year-over-year increase of 52.78%. This contributed to the annual value of -$8.36 for FY2025, which is 58.49% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported EPS (Basic) of -$0.44 as of Q3 2025, which was down 2.33% from -$0.43 recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' EPS (Basic) ranged from a high of $0.28 in Q2 2023 and a low of -$15.24 during Q3 2023.
  • Moreover, its 3-year median value for EPS (Basic) was -$2.71 (2024), whereas its average is -$3.24.
  • As far as peak fluctuations go, InMed Pharmaceuticals' EPS (Basic) surged by 102.15% in 2023, and later tumbled by 1,407.14% in 2024.
  • Over the past 5 years, InMed Pharmaceuticals' EPS (Basic) (Quarterly) stood at -$7.73 in 2021, then spiked by 88.23% to -$0.91 in 2022, then slumped by 307.69% to -$3.71 in 2023, then climbed by 1.89% to -$3.64 in 2024, then soared by 83.76% to -$0.44 in 2025.
  • Its EPS (Basic) stands at -$0.44 for Q3 2025, versus -$0.43 for Q2 2025 and -$1.94 for Q1 2025.